Betalin Therapeutics

The Engineered Micro Pancreas restores the body's insulin generation capabilities

Worldwide, 387 million people suffer from diabetes (WHO, 2015). Of these, 153 million people are treated with insulin injections, $24B annual revenues. To provide an effective treatment for diabetes, Betalin Therapeutics ('Betalin') is developing the Engineered Micro Pancreas (EMP), a breakthrough technology that within few days following a simple under the skin injection of EMPs, the patient will no longer need to use insulin injections and will restore the body's intrinsic insulin generation capabilities. Since diabetes is a huge market with unmet need (insulin revenues are $24b/year), Betalin has a relatively fast regulatory track, and that there are two family of patents accepted already in Europe and USA, there is a huge investment opportunity. Betalin is seeking for $3M and this will allow activity that will increase company value 10 times the least!

Stage

Pre-Clinical

Markets

Regenerative Medicine

Seeking

$3M